Review ArticleReview Article
Mechanisms and Drug Development in Atrial Fibrillation
David Calvo, David Filgueiras-Rama and José Jalife
Lori L. Isom, ASSOCIATE EDITOR
Pharmacological Reviews July 2018, 70 (3) 505-525; DOI: https://doi.org/10.1124/pr.117.014183
David Calvo
Department of Cardiology, Arrhythmia Unit, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain (D.C.); Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (D.F.-R., J.J.); Department of Cardiology, Arrhythmia Unit, Hospital Clínico Universitario San Carlos, Madrid, Spain (D.F.-R.); Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (D.F.-R., J.J.); and Center for Arrhythmia Research, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (J.J.)
David Filgueiras-Rama
Department of Cardiology, Arrhythmia Unit, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain (D.C.); Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (D.F.-R., J.J.); Department of Cardiology, Arrhythmia Unit, Hospital Clínico Universitario San Carlos, Madrid, Spain (D.F.-R.); Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (D.F.-R., J.J.); and Center for Arrhythmia Research, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (J.J.)
José Jalife
Department of Cardiology, Arrhythmia Unit, Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain (D.C.); Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (D.F.-R., J.J.); Department of Cardiology, Arrhythmia Unit, Hospital Clínico Universitario San Carlos, Madrid, Spain (D.F.-R.); Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain (D.F.-R., J.J.); and Center for Arrhythmia Research, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan (J.J.)
Lori L. Isom
Roles: ASSOCIATE EDITOR
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Review ArticleReview Article
Mechanisms and Drug Development in AF
David Calvo, David Filgueiras-Rama and José Jalife
Pharmacological Reviews July 1, 2018, 70 (3) 505-525; DOI: https://doi.org/10.1124/pr.117.014183
Jump to section
- Article
- Visual Overview
- Abstract
- I. Introduction
- II. Definitions
- III. Epidemiology of Atrial Fibrillation
- IV. Genetics of Atrial Fibrillation
- V. Pathophysiology of Atrial Fibrillation
- VI. Status of Antiarrhythmic Drugs in Atrial Fibrillation
- VII. New Drug Uses and New Molecular Mechanisms
- VIII. Novel Targets in Atrial Fibrillation
- IX. Atrial Fibrillation and Sleep Apnea
- X. Challenges and Opportunities in New Anti-atrial Fibrillation Drug Development
- XI. Conclusion
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement